
Implementing A New CEO Strategy With NervGen's Adam Rogers, M.D. And Rich Macary
Episode 303
We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, we talk with NervGen leaders Adam Rogers, M.D., and Rich Macary about NVG-291, a daily neuroreparative peptide designed to restore function in patients with spinal cord injuries. Adam talks about his strategy for the company after becoming CEO last July, including moving company trading from Canada's TSX Venture Exchange to the NASDAQ for better visibility, and making key hires for growth. Rich talks about his early work in RNA therapeutics as an advisor at Sarepta, cofounding Synaptica Therapeutics, and bringing Adam to NervGen. They also talk about engaging with the FDA on endpoints for NVG-291's Phase 3 trial, and the broader opportunity in neurotrauma. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/
Publisher
Business Of Biotech
Published
April 27, 2026
Duration
48 min
Format
Podcast
Category
Issues · Business
Source
RSS feed
Host
Ben Comer
Business Of Biotech
@businessofbiotech
#ceostrategy #nervgensadamrogers #richmacary #management #lifesciences
